I agree with Easy Street. I think the next announcement will be about the FDA's response re: the number of Phase 3 trials required. We're expecting that the FDA - once they see the Phase 2 data - will only ask IXC to conduct one trial (in line with the EMA's recommendation). If this happens, we should see a rise in the share price. As FiftyOneCapital stated in their podcast, the stock will likely re-rate once the Phase 3 trials are under way, so we just need to be patient (IMO, DYOR)
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
9.0¢ |
Change
0.000(0.00%) |
Mkt cap ! $6.763M | |||
| Open | High | Low | Value | Volume |
| 0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 7 | 9.2¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 9.7¢ | 9000 | 1 |
View Market Depth
| Last trade - 16.21pm 16/07/2025 (20 minute delay) ? |
| IXC (ASX) Chart |
Day chart unavailable